$14,047.38 consulting Payment -- Takeda Pharmaceuticals to Dr. Paul Turner
Rare Disease Specialist Receives $14,047 Consulting Fee from Takeda Pharmaceuticals for Ozempic-Related Work
This page provides a detailed analysis of a $14,047.38 consulting payment from Takeda Pharmaceuticals to Dr. Paul Turner. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $14,047.38 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Takeda Pharmaceuticals |
| Physician | Dr. Paul Turner |
| NPI Number | 1817237397 |
| Physician Specialty | Rare Disease |
| Location | City, IN |
| Date of Payment | 2026-03-14 |
| Related Drug/Device | Ozempic |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Takeda Pharmaceuticals made a $14.0K consulting payment to Paul Turner, a Rare Disease specialist in City, IN. The payment was associated with Ozempic. The payment of $14,047.38 to Dr. Paul Turner for consulting services is a significant amount for a single engagement. The payment is associated with Ozempic, a drug used for diabetes and weight management, which may indicate a focus on metabolic aspects within rare disease research or patient care. The payment occurred on March 14, 2026, suggesting a future engagement or a reporting lag.
Patient Guidance: What This Payment Means for You
If you are a patient with a rare disease, understand that your doctor may receive payments for consulting on treatments, which could include medications like Ozempic, to help advance medical knowledge. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Consulting fees for rare disease specialists can vary widely, but $14,047.38 for a single payment is on the higher end, especially if the consultation is directly tied to a specific drug's use in a non-standard indication.
Regulatory Context: Sunshine Act Requirements
Physicians receiving payments from pharmaceutical companies for consulting services must ensure these arrangements comply with federal regulations, including disclosure requirements under the Open Payments program and adherence to anti-kickback statutes.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-consulting
- rare-disease
- ozempic
- takeda-pharmaceuticals
- physician-payment
- consulting-fee
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $14.0K payment for?
This was a consulting payment of $14.0K from Takeda Pharmaceuticals to Paul Turner, categorized as "Consulting Fee". It was associated with Ozempic. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Paul Turner accept pharmaceutical money?
Yes, Paul Turner received this $14.0K payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Paul Turner's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $14.0K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Rare Disease?
To compare this payment against Rare Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Rare Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Paul Turner's relationship with Takeda Pharmaceuticals?
The payment type is 'consulting', specifically a 'Consulting Fee', indicating direct engagement for expertise. This $14.0K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Rare Disease?
The specialty listed is 'Rare Disease', which might seem unusual for Ozempic, prompting further investigation into the specific context of the consultation.
What should patients do after learning about this payment?
If you are a patient with a rare disease, understand that your doctor may receive payments for consulting on treatments, which could include medications like Ozempic, to help advance medical knowledge.
What else should I know about this consulting payment?
The amount is substantial, suggesting a complex or lengthy consulting project.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.